Official Website: Myriad Genetics
source confidence: Medium status: Useful updated 2026-08-11
Summary
Myriad Genetics's official website describes its clinical genetic and genomic testing portfolio across hereditary cancer risk, reproductive health, oncology, urology, and mental health pharmacogenomics.
Useful Claims
- Myriad says it has partnered with the healthcare community for more than 30 years to advance genetics and tumor genomic profiling.
- The site organizes tests into five health areas: hereditary cancer risk, reproductive health, oncology, urology, and mental health.
- Hereditary cancer products are described as helping detect risk across multiple cancer types; the site references tests covering 11 hereditary cancers.
- Oncology offerings include germline and tumor genomic tests intended to support screening, treatment, and survivorship decisions.
- Reproductive-health products include carrier screening, prenatal chromosomal testing, and early fetal-sex determination.
- Urology products include Prolaris; as of the 2026-06-19 fetch the homepage highlighted Prolaris + AI combining genomics with AI-driven digital pathology for active-surveillance management (not present 2026-08-11 — see Reliability Notes).
- Mental-health offerings use pharmacogenomics to inform antidepressant and related medication selection.
- As of the 2026-06-19 fetch the site claimed one of the largest repositories of comparative variant data covering all ancestries (not present 2026-08-11).
Verbatim
"For more than 30 years, we've partnered with the healthcare community to advance the science of genetics and tumor genomic profiling." — Home page, opening statement (fetched 2026-08-11)
"Identifies risk of developing 11 hereditary cancers" — Home page, hereditary cancer product card (fetched 2026-08-11)
Understanding hereditary cancer risk What is my risk of developing hereditary cancer? — Home page, patient navigation label (fetched 2026-08-11)
Managing mental health How might my genes affect my medication outcomes? — Home page, patient navigation label (fetched 2026-08-11)
Reliability Notes
Self-reported tier. This is useful for product categories, patient and provider positioning, and current menu structure. It carries no weight for company size, finances, or headquarters — use Source: Myriad Genetics Form 10-K, Fiscal Year 2025, which is primary and which corrects the Research Park address that third-party directories still repeat. Test performance, market share, and clinical-outcome claims need peer-reviewed publications or FDA/LDT documentation.
Drift note. Two claims recorded from this page on 2026-06-19 could not be re-confirmed in the 2026-08-11 fetch: the "Prolaris + AI" digital-pathology highlight, and the assertion of one of the largest repositories of comparative variant data covering all ancestries. They are retained above as a record of what the site said on the earlier date, not as current claims. This is the ordinary behaviour of a marketing homepage and the reason self-reported sources are quoted and archived at the moment they are cited.